熱門資訊> 正文
Johnson & Johnson seeks approval of pediatric indications for TREMFYA
2024-12-02 21:40
- Johnson & Johnson (NYSE:JNJ) submitted two supplemental Biologics License Applications to the U.S. FDA seeking approval of TREMFYA for treating children 6 years and older with moderate-to-severe plaque psoriasis (PsO) and children 5 years of age and older with active juvenile psoriatic arthritis.
- The submission is based on data from the late stage study in pediatric patients with moderate to severe plaque PsO and bridging pharmacokinetic data from the Phase 3 VOYAGE 1 and 2 studies.
- Source: Press Release
More on Johnson & Johnson
- How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding
- Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
- Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
- Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC
- Johnson & Johnson seeks FDA approval for its ulcerative colitis treatment
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
